PHAT: Phathom Pharmaceuticals Company Short-Term Debt

Symbol and logo of brand Phathom Corp (PHAT)

Phathom Pharmaceuticals (PHAT) relies on advanced US R&D centers while outsourcing the production of gastrointestinal drugs to third-party contractors. This chart illustrating the price evolution of the shares demonstrates the asset's dynamics, where the indicator stands at 0.00. The business focuses on the therapy of acid-related pathologies within its laboratories, and the rapid demand for Voquezna in the treatment of esophagitis is currently actively driving the growth of the company's total revenue.

PHAT (Phathom Pharma) Company Short-Term Debts history from 07/04/2022 to 10/30/2026

Analytical breakdowns for Phathom Pharmaceuticals

- current quotes and average value forecast:
Price Chart Phathom Pharmaceuticals, Inc.|PHAT - Fair Value Consensus
- market capitalization information:
Market Value Phathom Pharmaceuticals, Inc.|PHAT - Real Price to Acquire Entire Company
- shareholders' equity book value data:
Book Value per Share Phathom Pharmaceuticals|PHAT - Book Capitalization|Market Cap to Net Assets Ratio phathompharma.com|PHAT - Aggregate Asset Value
- debt and liquidity data:
Total Debt to Capital Phathom Pharmaceuticals|PHAT - Long-Term Indebtedness to Equity|Short-Term Debt to Capital Phathom Pharmaceuticals|PHAT - Company Total Debt Obligations|Debt to Book Value Phathom Pharmaceuticals, Inc.|PHAT - Amount of Long-Term Liabilities|Company Short-Term Debt Phathom Pharmaceuticals|Quick Ratio phathompharma.com
- net income and valuation multiples indicators:
PHAT - Final Profit
Fundamental company analysis:Phathom Pharmaceuticals, Inc. - PHAT
Manufactured products of Phathom

Rising sales of gastrointestinal drugs and expanded insurance coverage are stabilizing the cash flows of Phathom Pharmaceuticals (PHAT). This metric aggregates all liabilities maturing within one year to assess the issuer's current solvency. While debt reduction confirms available liquidity, it may signal a slowdown in expansion. Investors utilize this indicator for a rapid screening of financial stability. The trend in short-term liabilities reflects the balance between product launch costs and operational efficiency.

Who Phathom Pharmaceuticals competes with

TERN - Company Short-Term Debt|Company Short-Term Loans and Borrowings IRWD (Ironwood Pharmaceuticals)|curanexpharma.com (CURX) - Company Short-Term Debt|Company Current Liabilities Immuron|EVOK (Evoke Pharma, Inc.) - Company Short-Term Debts|Company Short-Term Debts Entero|Company Current Liabilities RDHL (RedHill Biopharma)|PALI (palisadebio.com) - Company Short-Term Loans and Borrowings|Company Short-Term Debts JAGX (Jaguar Animal Health)|Short-Term Indebtedness Biora Therapeutics, Inc|Morphic Holding, Inc. - Company Short-Term Debts